脑肿瘤疫苗。

Brain Tumor Vaccines.

机构信息

UCLA Department of Neurosurgery, David Geffen School of Medicine at UCLA, University of California Los Angeles, 300 Stein Plaza Driveway Suite 420 Los Angeles, CA 90095, USA.

出版信息

Neurosurg Clin N Am. 2021 Apr;32(2):225-234. doi: 10.1016/j.nec.2021.01.003.

DOI:10.1016/j.nec.2021.01.003

PMID:33781504

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11695044/

Abstract

Peptide and dendritic cell vaccines activate the immune system against tumor antigens to combat brain tumors. Vaccines stimulate a systemic immune response by inducing both antitumor T cells as well as humoral immunity through antibody production to cross the blood-brain barrier and combat brain tumors. Recent trials investigating vaccines against peptides (ie, epithelial growth factor receptor variant III, survivin, heat shock proteins, or personalized tumor antigens) and dendritic cells pulsed with known peptides, messenger RNA or unknown tumor lysate targets demonstrate the potential for therapeutic cancer vaccines to become an important therapy for brain tumor treatment.

摘要

肽和树突状细胞疫苗通过诱导抗肿瘤 T 细胞和产生抗体来穿过血脑屏障并对抗脑肿瘤，从而激活针对肿瘤抗原的免疫系统以对抗脑肿瘤。最近的研究表明，针对肽（例如表皮生长因子受体变体 III、存活素、热休克蛋白或个性化肿瘤抗原）和用已知肽、信使 RNA 或未知肿瘤裂解物靶向物冲击的树突状细胞的疫苗具有治疗癌症疫苗成为脑肿瘤治疗的重要治疗方法的潜力。